Stockreport

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Larimar Therapeutics, Inc.  (LRMR) 
PDF Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations [Read more]